반응식
[CH3:1][NH:2][CH2:3][CH2:4]/[CH:5]=[C:6]1\[C:7]2[C:12]([CH2:13][O:14][C:15]3[C:20]\1=[CH:19][CH:18]=[CH:17][CH:16]=3)=[CH:11][CH:10]=[CH:9][CH:8]=2.P([O-])([O-])([O-])=[O:22].[Na+].[Na+].[Na+]>C1COCC1.[Zn]>[CH2:20]1[CH2:15][O:14][CH2:18][CH2:19]1.[CH3:13][OH:14].[NH4+:2].[OH-:22].[CH3:1][NH:2][CH2:3][CH2:4]/[CH:5]=[C:6]1\[C:7]2[C:12]([CH2:13][O:14][C:15]3[C:20]\1=[CH:19][CH:18]=[CH:17][CH:16]=3)=[CH:11][CH:10]=[CH:9][CH:8]=2참가 물질
6
실험 절차
The N-protected (E)-desmethyldoxepin intermediate (1.44 g, 3.27 mmol) was dissolved in 12 mL THF, 2.88 g of zinc powder added, 2.3 mL of 1M sodium phosphate (pH=5.5) added, and reaction stirred for 17 hours. The reaction mixture was then vacuum filtered, filtrate solvent removed in vacuo, and resulting residue purified by silica gel column chromatography, eluting with THF/MeOH/NH4OH (85/15/0.4), then THF/MeOH/NH4OH (75/25/0.4), to afford 744 mg (2.80 mmol) of the desired product [3] as a pale yellow solid; 1H NMR (200 MHz, CDCl3): d 2.5 (s, 3H), 2.7 (m, 2H), 3.0 (m, 2H), 4.7-5.8 (broad s, 2H), 6.0 (t, 1H), 6.8-6.9 (m, 2H), 7.1-7.4 (m, 6H); mass spec (FAB): (M+H)+266.
후처리
- customreaction
- filtrationvacuum filtered
- customfiltrate solvent removed in vacuo
- customresulting residue
- custompurified by silica gel column chromatography
- washeluting with THF/MeOH/NH4OH (85/15/0.4)
출처 및 근거
- ORD 기록
- ord-fb20430bebd94c4096165067143b32bf
- 출처 데이터셋
- uspto-grants-1994_07
- 특허 번호
- US05332661
연결된 노트
불러오는 중…